首页|二陈汤合三子养亲汤治疗慢性支气管炎的系统评价与meta分析

二陈汤合三子养亲汤治疗慢性支气管炎的系统评价与meta分析

扫码查看
目的:系统评价二陈汤合三子养亲汤治疗慢性支气管炎的疗效及安全性。方法:通过计算机检索中国知网、万方、维普、中国生物医学文献数据库、Web of Science、PubMed、Cochrane Library、Embase数据库,收集二陈汤合三子养亲汤治疗慢性支气管炎的随机对照试验,检索时间时限从各数据库建库至2023年3月31日,同时检索临床注册试验和灰色文献。对最终纳入的研究采用Cochrance风险偏倚评估工具进行质量评价与偏倚风险评估,并运用RevMan 5。3软件对最终纳入研究进行Meta分析。结果:共纳入13篇RCT文献,共涉及了978例患者,其中治疗组490例,对照组488例。Meta分析结果显示:二陈汤合三子养亲汤干预治疗慢性支气管炎,在临床疗效方面,可以显著提高临床总有效率[OR=3。71,95%CI(2。39,5。75),P<0。000 01];在症状、体征方面,可以缩短咳嗽停止时间[MD=-4。73,95%CI(-5。63,-3。83),P<0。000 01]、喘息停止时间[MD=-3。78,95%CI(-4。30,-3。27),P<0。000 01]、肺部啰音消失时间[MD=-4。15,95%CI(-4。82,-3。73),P<0。000 01];在肺功能方面,能改善FEV1[MD=0。33,95%CI(0。25,0。40),P<0。000 01],改善FEV1/FCV[MD=16。21,95%CI(1。48,30。94),P=0。03];在炎症因子方面,能降低WBC[MD=-3。02,95%CI(-3。55,-2。50),P<0。000 01]、CRP[MD=-15。79,95%CI(-20。53,-11。04),P<0。000 01]、TNF-α[MD=-8。96,95%CI(-13。45,-4。46),P<0。000 01]。纳入的文献均未报道严重不良反应。结论:二陈汤合三子养亲汤干预治疗慢性支气管炎,可以显著提高临床疗效,缩短患者咳嗽、喘息、肺部啰音消失时间,改善患者的肺功能,降低患者炎症因子水平,安全性有待进一步验证,但是纳入文献的方法质量学总体不高,纳入文献的数量较少,仍需要更多高质量、大样本、多中心的RCT支持。
A systematic review and meta-analysis of erchen decoction and sanzi yangqin decoction in the treatment of chronic bronchitis
Objective:To systematically evaluate the efficacy and safety of Erchen decoction and Sanzi Yangqin decoction in the treatment of chronic bronchitis.Methods:The randomized controlled trials of Erchen decoction and Sanzi Yangqin decoction in the treatment of chronic bronchitis were collected from CNKI,Wan Fang data,VIP,CBM,Web of Science,PubMed,Co-chrane Library,and Embase databases,and the literature was screened from the establishment of the database to March 31,2023,and both clinical registration trials and gray literature were searched.The final included studies were evaluated for quality and risk of bias using the Cochrance risk of bias assessment tool,and meta-analysis was performed on the final included studies using Rev-Man 5.3 software.Results:A total of 13 RCTs involving 978 patients,including 490 patients in the treatment group and 488 pa-tients in the control group,were included,and the results of the meta-analysis showed that the clinical efficacy of Erchen decoction and Sanzi Yangqin decoction intervention for the treatment of chronic bronchitis significantly improved the total clinical efficiency[OR = 3.71,95%CI(2.39,5.75),P<0.000 01].In terms of symptoms and signs,it could shorten the cessation time of cough[MD =-4.73,95%CI(-5.63,-3.83),P<0.000 01],wheeze cessation time[MD =-3.78,95%CI(-4.30,-3.27),P<0.000 01],lung rales disappearance time[MD =-4.15,95%CI(-4.82,-3.73),P<0.000 01];in terms of lung function,it improved FEV1[MD = 0.33,95%CI(0.25,0.40),P<0.000 01]and FEV1/FCV[MD = 16.21,95%CI(1.48,30.94),P = 0.03];in terms of inflammatory factors,it reduced WBC[MD =-3.02,95%CI(-3.55,-2.50),P<0.000 01],CRP[MD =-15.79,95%CI(-20.53,-11.04),P<0.000 01],TNF-α[MD =-8.96,95%CI(-13.45,-4.46),P<0.000 01].No serious adverse reactions were reported in the included literature.Conclusion:The intervention of Er Chen Tang combined with San Zi Yang Yin Tang for the treatment of chronic bronchitis can significantly improve clinical efficacy,shorten the time to disappearance of cough,wheezing,and pulmonary rales,improve patients'lung function,and reduce patients'inflammatory factor levels,with safety to be further validated,but the methodological quality of the included literature is generally not high and the number of included literature is low,and more high-quality,more large sample,and multicenter RCTs support.

Erchen decoction and Sanzi Yangqin decoctionChronic bronchitisSystematic reviewMeta-analysis

黄秋红、李佳栩、蔡家伟、周佳麒、王光耀、许光兰

展开 >

广西中医药大学研究生院,广西 南宁 530001

广西中医药大学第一附属医院,广西 南宁 530023

二陈汤合三子养亲汤 慢性支气管炎 系统评价 Meta分析

国家自然科学基金广西壮族自治区高等学校中青年教师科研基础能力提升项目广西医疗卫生重点培育学科建设项目

817608482021KY310

2024

海南医学院学报
海南医学院

海南医学院学报

CSTPCD北大核心
影响因子:1.068
ISSN:1007-1237
年,卷(期):2024.30(8)
  • 42